![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
GSK plc | NYSE:GSK | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.11 | -0.27% | 39.90 | 40.005 | 39.49 | 39.97 | 4,916,753 | 22:16:55 |
By Ian Walker
GlaxoSmithKline PLC said Wednesday that it is partnering with Eli Lilly & Co. and Vir Biotechnology Inc. to evaluate a combination of two Covid-19 therapies in low-risk patients with mild-to-moderate symptoms of the virus.
Under the collaboration, Lilly has expanded a trial of its Bamlanivimab antibody to include Vir and Glaxo's VIR-7831 monoclonal antibody.
Bamlanivimab is a neutralizing antibody directed against the spike protein of SARS-CoV-2, designed to block viral attachment and entry into human cells, and therefore neutralize the virus.
Vir and Glaxo's VIR-7831 antibody drug has the potential to both block viral entry into healthy cells and clear infected cells, as well as provide a high barrier to resistance, the companies said.
Lilly's Chief Scientific Officer Daniel Skovronsky said that trials of Bamlanivimab have demonstrated "robust evidence" for both treating and preventing Covid-19.
"Despite the significant progress on vaccines, there remains an urgent patient need for multiple therapeutic approaches to help prevent the severe consequences of Covid-19," Glaxo Chief Scientific Officer Dr. Hal Barron said.
Lilly's Bamlanivimab on its own has already been authorized by the U.S. Food and Drug Administration for treating people sick with mild-to-moderate Covid-19 cases. Vir and Glaxo's VIR-7831 is being evaluated in two late-stage trials for treatment of hospitalized patients and as an early treatment in adults at high risk of hospitalization.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
January 27, 2021 06:59 ET (11:59 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions